<DOC>
	<DOCNO>NCT01090089</DOCNO>
	<brief_summary>In study elderly myeloma patient lenalidomide plus low-dose dexamethasone progression compare age-adjusted tandem high-dose melphalan 140 mg/m² augment induction 3 cycle lenalidomide plus low-dose dexamethasone transplantation lenalidomide maintenance transplantation .</brief_summary>
	<brief_title>Combination Lenalidomide Dexamethasone Treatment Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age 6075 year time signing informed consent form . 3 . Able adhere study visit schedule protocol requirement . 4 . Symptomatic MM require therapy . 5 . Measurable monoclonal protein serum and/or urine 6 . Monoclonal plasma cell bone marrow &gt; /= 10 % and/or biopsyproven plasmacytoma 7 . Myelomarelated organ dysfunction , least one [ C ] Calcium elevation serum ( &gt; 11.5 mg/dL &gt; 2.65 mmol/l ) [ R ] Renal insufficiency ( creatinine &gt; 173 μmol/l &gt; 2 mg/dL ) [ A ] Anemia ( Hb &lt; 10 g/dL 2 g/dL &lt; normal ) [ B ] Bone lesions general osteoporosis 8 . ECOG PS &lt; /= 2 ... 9 . Laboratory test result within range within 1 week prior randomization : ANC &gt; /= 1.0 x 109/L . Platelet count &gt; /= 75 x 109/L case bone marrow infiltration myeloma cell &gt; /= 30 x 109/L . Total bilirubin &lt; /= 2 mg/dL . AST ( SGOT ) ALT ( SGPT ) &lt; /= 3 x ULN . 8 . Female subject childbearing potential must : Understand study drug expect teratogenic risk Agree use , ... , effective contraception without interruption , ... Understand even amenorrhea , must follow advice effective contraception . She understand potential consequence pregnancy need rapidly consult risk pregnancy Agree medically supervise pregnancy test ... Male subject must Agree use condom throughout study drug therapy , dose interruption one week cessation study drug therapy ... Agree donate semen study drug therapy one week end study drug therapy . All subject must Agree abstain donate blood take study drug therapy one week follow discontinuation study drug therapy . Agree share study drug another person return unused study drug investigator . 9 . Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . 10 . Able receive antithrombotic prophylaxis ( ... ) . 11 . Lifeexpectancy &gt; 3 month . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign ICF . 2 . Pregnant lactating female 3 . Any condition , incl . presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 4 . Patient currently enrol another clinical research study enrol ... within 4 week randomization and/or receive investigational agent reason ... 5 . Known hypersensitivity thalidomide , dexamethasone , melphalan . 6 . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . 7 . Any prior use lenalidomide . 8 . Concurrent use anticancer agent treatment . 9 . Known positive HIV active infectious hepatitis , type A , B C treponema pallidum 10 . Prior treatment dexamethasone discontinue ≥ grade 3 dexamethasonerelated toxicity . 11 . Any prior chemotherapy exception short course dexamethasone 4 week randomization . 12 . Immunotherapy antibody therapy within 8 week randomization . 13 . Major surgery within 4 week randomization . 14 . Renal failure require dialysis . 15 . Myocardial infarction within 6 month randomization , NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . 16 . Severe pulmonary disease ( diffusion capacity &lt; 60 % normal ) . 17 . Treatment cancer MM within 5 year randomization , exception basal cell carcinoma cervical cancer situ . 18 . Cardiac amyloidosis . 19 . Poorly control hypertension , diabetes mellitus , serious medical psychiatric illness could potentially interfere completion treatment accord protocol . 20 . Any systemic infection require treatment . 21 . Unability unwillingness patient receive antithrombotic prophylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>